We work with global biotech, pharma, government and NGOs in the design, execution, and commercialisation of vaccines to prevent infectious diseases.
The number of new and re-emerging infectious diseases continues to rise and pose a threat to world health. Our global team have built up extensive vaccine expertise, with over 200 years experience across our leadership team alone. This enables us to anticipate the challenges in your drug development plan and consistently beat aggressive vaccine start up timelines and enrolment goals. We are applying this experience to the COVID-19 vaccine trials we are currently running. We focus on driving your milestone success and on providing high quality deliverables within budget.
Our work has resulted in 17 vaccine approvals by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA). And our team have winners of “Best CRO” at the Vaccine Industry Excellence (ViE) Awards three times (2020, 2017 and 2014) and have been named a finalist every year since 2011.
We are also prime contractors for the US Government and qualified provider for the Bill and Melinda Gates Foundation. Our broad portfolio of services and global footprint also serve the needs of other global health organisations such as Wellcome Trust, Global Fund and CEPI.
ICON vaccine experience in the last five years
185Studies conducted, including over 40 studies in respiratory viruses such as COVID-19
296,901Patients involved, spanning vaccine types, populations, indications
3,992Vaccine experienced sites in over 40 countries
Experience our partners can trust
Our team understands the urgency, complexities, and potential challenges associated with running trials in normal times. During this pandemic we are running over 130 COVID-19 trials and have extensive prophylactic vaccine study experience. ICON provided clinical trial services to the Pfizer and BioNTech SE investigational COVID-19 vaccine programme. We make data-driven recommendations and apply best practices to execute your COVID-19 study, while safeguarding trial participants. By selecting us as your contract research organization (CRO) partner, you will benefit from:
- A leadership team focused specifically in Vaccines with well over 100 years of combined experience in vaccine clinical development who provide insight into your protocol and strategies to operationalize execution
- Direct involvement in the design, implementation and / or execution of clinical trials
- Specialized, scalable infectious disease and vaccine-experienced resources ready to deploy for COVID-19 studies
- Global Site Network and Patient Solutions comprised of ICON’s proprietary vaccine-experienced sites with PBMC isolation capabilities that are prepared to conduct COVID-19 vaccine trials
- FIRECREST digital solutions including an Investigator Portal for document distribution and protocol-specific training for site staff
Vaccines experience & capabilities
Our vaccine research experience encompasses prophylaxes for seasonal, vector, sexually-transmitted, enteric and other viral and bacterial infections across all populations including maternal participants.
Watch the videos below for an overview of ICON's experience and capabilities in vaccines, including details of vaccine types, participant populations and indications, as well as the range of our services.
Our Vaccines service offerings
Our extensive services include:
- Clinical monitoring and study management
- Expert consultation and operational delivery Phase I-IV
- Life cycle management and outcomes research protocol development
- Regulatory consultancy with phase specific quality systems
- Medical affairs and pharmacovigilance
- Data management and biostatistics
- Vaccine government experience
- Patient recruitment
COVID-19 clinical operations
Keeping your clinical trial on track in an evolving environment.
Adapting operations to changing conditions
ICON has adapted its services to support sponsors during this time; offering remote monitoring where on-site visits were not permitted, providing additional support to get IMP to patients and pre-recording investigator meetings because of travel restrictions.
Treatment and vaccine trials for COVID-19
ICON is proud to be supporting clients and government organisations in the search for a treatment or vaccine for COVID-19. Download our whitepaper on Pandemic respiratory vaccine clinical trials.
Accellacare, ICON's Global Site Network
Accellacare, ICON's Global Site Network combines our proprietary site network and healthcare alliance sites across North America, Europe, Africa and Middle East to provide greater access to patients and multi-specialty physicians for our clients. This network of research sites, offers proven, professional clinical research resources and infrastructure for your clinical research.
Adaptive design trials
We are the only full service CRO with the knowledge, software, systems, and global footprint to make adaptive clinical trials a reality. Our full service includes the design, simulation, and execution of adaptive clinical trials that can be effectively applied in these studies.
Our proprietary software ADDPLAN enables design, simulation, and analysis of adaptive clinical trials with ease and enables faster decision making at critical points during trial execution.
Digital solutions for education and automation to increase efficiency in clinical trials
FIRECREST digital solutions provide you with the tools and support to move your training on line - whether it is the training that you would usually deliver in group meetings or the training that CRAs provide on site.
The FIRECREST Study Portal, which is fully customisable to your study, provides single sign-on to a range of education and automation solutions. Connectivity to site and study staff will lead to increased engagement and improved study performance.
Infectious diseases and vaccines insights
ICON's Infectious Diseases and Vaccines teams contribute regularly to media and industry conversations in addition to the production of thought leadership content in the form of whitepapers and blogs.Read more